Among 183 depressed patients participating in a randomized long-term treatment trial of fluoxetine and nortriptyline, 30 patients had borderline personality disorder (BPD), 53 had other personality disorders (OPD), and 100 had no personality disorders (NPD). The borderline depressed patients had earlier age of onset of their depressions, more chronic depressions, more alcohol and cannabis comorbidity, and were more likely to have histories of suicide attempts and of self-mutilation. On self-report, patients with BPD and OPD reported more phobic symptoms, greater interpersonal sensitivity, and more paranoid ideation.
B
ORDERLINE personality disorder (BPD) is frequently comorbid with major depression. The reasons for this comorbidity remain controversial, and range from BPD being a forme fruste of affective disorders, 1 to major depression being a complication of and secondary to BPD, 2 to intermediate hypotheses that acknowledge shared risk factors. 3 Whatever the reasons for this comorbidity, many clinicians are challenged by the behavior of such patients, and by their management. Furthermore, in many treatment studies of major depression, patients with BPD are excluded. 4 Presumably, the exclusion of patients with comorbid BPD reflects a belief that such depressed patients have a different response to treatment, or that the suicide risk of such patients is unacceptably high for a research study.
Over the past decade, one of the more interesting developments in the area of personality psychopathology has been the psychobiological model of temperament and character developed by Cloninger. 5 In this model, there are four dimensions of temperament: novelty seeking, harm avoidance, reward dependence and persistence, which are independently heritable, manifest early in life, and involve preconceptual biases in perceptual memory and habit formation. Cloninger also describes three dimensions of character, which develop by insight learning about self-concepts. The character dimensions relate to an individual's concept of themselves as autonomous individuals (self-directedness), in relationship to others (cooperativeness), and in relationship to the universe (self-transcendence). These seven domains of personality may be assessed by the Temperament, Character Inventory (TCI).
Within the framework of Cloninger's model of personality, patients with BPD will share the features of all patients with personality disorders, in that they will have low self-directedness (blaming of others and lack of goal direction) and low cooperativeness (socially intolerant, unhelpful, and revengeful). In addition, patients with BPD have high scores on the temperament measures of novelty seeking and harm avoidance. Temperamentally, BPD patients, therefore, have an approach (novelty seeking)-avoidance (harm avoidance) conflict. Emotionally, the high novelty seeking and high harm avoidance will make them prone to euphoria, anger, anxiety, and depression, depending upon reward and punishment contingencies. 6, 7 Here, we compare depressed patients who have a comorbid BPD with depressed patients who have other personality disorders (OPD) or no personality disorder (NPD). We compare the BPD depressed group with the other two depressed groups in relationship to clinical variables, comorbidity, symptom pattern, suicidal and self-harm history, and social functioning. We also examine the extent to which we replicate the findings of Svrakic et al. 6 that BPD is associated with low self-directedness, low cooperativeness, high novelty seeking, and high harm avoidance. Then, we examine whether a comorbid BPD has implications for the short-term (6-week) treatment of depression in a randomized treatment trial of fluoxetine versus nortriptyline. Finally, we look at the 6-month outcome for depressed patients with BPD, both in relationship to depression and personality variables.
METHODS

Subjects
The depressed patients for this study were recruited as part of the Christchurch Outcome of Depression Study, 8 which has a major objective of looking at predictors of antidepressant response. [9] [10] [11] For inclusion in this study, the current principal diagnosis needed to be major depression, and the treating clinician considered that treatment with an antidepressant drug was appropriate. Apart from the oral contraceptive and an occasional hypnotic, patients were required to be free of all psychotropic drugs for a minimum of 2 weeks. Depressed patients were excluded only if alcohol and/or drug dependence was considered the current principal diagnosis. Current alcohol and/or drug dependence was allowed if the treating clinician judged major depression to be the current principal diagnosis. Patients were also excluded if they had a history of schizophrenia or bipolar I disorder, but patients with a history of hypomania (bipolar II) were included. If antisocial personality disorder appeared to be the principal current diagnosis, these patients were also excluded. Patients were required to be free of major medical illness (e.g., diabetes). The study was approved by the local ethics committee.
Baseline Evaluation
After an initial psychiatric evaluation and giving written informed consent, patients attended the Clinical Research Unit for a detailed baseline research evaluation.
Patients were assessed by their treating psychiatrist or senior psychiatric resident using the Structured Clinical Interview for DSM-III-R. 13 The depression section was expanded for this study to include all the DSM-III-R and DSM-IV criteria for melancholia and atypical depression. Patients were also rated on the 17-item and 27-item Hamilton Depression Rating Scale (HDRS), 12 and on the Montgomery Asberg Depression Rating Scale (MADRS). 14 Patients completed a series of self-report questionnaires including the Hopkins Symptom Checklist (SCL-90), 15 the Social Adjustment Scale (SAS), 16 the TCI, 5 and the Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-PQ). 17 Patients reported to the Clinical Research Unit at 1 PM after a 3-hour fast for their neurobiological evaluation. This included routine checks of biochemistry, hemotology, and thyroid function tests, and research evaluation for mean afternoon cortisol levels, plasma neutral amino acids, a thyrotropin releasing hormone (TRH) challenge, and DNA for genetic analyses.
Over the subsequent weeks, after commencing treatment with an antidepressant drug, the treating psychiatrist completed an assessment of personality disorder criteria using the SCID-II. 18 By the time the psychiatrist completed this assessment, they had usually seen the patients on four to six occasions, had often seen a relative or friend of the patient, and had available the patient's self-report on the SCID-PQ. During this study, we conducted a reliability study on SCID-II interviews, and the kappa for presence/absence of a personality disorder was 0.71. At the same time as the SCID-II was completed, a family history of mental disorders in first-degree relatives was obtained.
Treatment
After the baseline evaluation, patients were randomly assigned to open treatment with either fluoxetine or nortriptyline. The randomization was undertaken by the research coordinator and research nurse, who told the treating psychiatrist which drug to use. Patients were then seen at least weekly for 20 to 40 minutes, depending on patient need. In the initial stages of treatment, emphasis was placed on ensuring a good trial with the antidepressant within the context of optimal clinical management.
If the patient was randomly assigned to nortriptyline, the initial dosing schedule was 25 mg for one night, 50 mg for one night, and then 75 mg. After 1 week, blood levels were obtained and further dosage adjustments were undertaken using clinical response, side effects, and blood levels. At 6 weeks, the mean dosage was 93 mg for those without BPD and 94 mg for those with BPD, and dosages ranged from 50 to 175 mg. The mean nortriptyline blood levels at 6 weeks of 313 and 321 nmol/L were again remarkably similar between those with and without BPD. The blood levels were monitored during the 6 weeks to ensure patients were within the therapeutic window of nortriptyline.
For patients randomly assigned to fluoxetine, the initial dosage was 20 mg daily for 3 weeks, although, in exceptional cases, this could be reduced to 10 mg to decrease side effects. At 3 weeks, the clinician was free to adjust dosage up to a maximum of 80 mg. At 6 weeks, the mean dosage was 28 mg, the most common dosage was 20 mg, and the range was 10 to 80 mg.
After 6 weeks of treatment, the psychiatrist, in conjunction with the patient, made a decision to continue with the initially prescribed antidepressant or to change antidepressant. Patients continued in open treatment with their psychiatrist over ensuing months with appointments flexible, depending on the patient's mental state and need.
Outcome
At 3, 6, 9, 13, 19, and 26 weeks, patients were reassessed. This involved the clinician rating patients on the HDRS and MADRS, and making a global clinical rating. In addition, patients completed the self-rating scales of the SCL-90 and SAS. At 6 months, patients again completed the TCI.
Of the initial 183, 79% (n ϭ 145) completed the self-report questionnaire and had clinician ratings at 6 months. Of the initial 30 depressed patients with borderline personality disorder, the 6-month outcome data were available on 73% (n ϭ 22).
Statistical Analyses
All data was entered into the relational database, PARADOX, and transferred to SYSTAT (1990) for statistical analyses. Analyses included chi-square, t test, analysis of variance, regression, and multiple regression.
RESULTS
Comparison of Borderline Depressed Patients With Other Depressed Patients
One hundred ninety-five depressed patients entered this study. Complete axis II interviews were completed on 183, who are the subjects of this reprot. Of the 183 depressed patients, 30 met DSM-III-R criteria for BPD, a further 53 met criteria for OPD, and 100 did not meet criteria for any personality disorder (NPD). Table 1 shows that those meeting criteria for BPD often met criteria for OPD. In those with OPD, the most common were avoidant, paranoid, obsessive-compulsive, and dependent. Table 2 shows that there is a nonsignificant trend for the BPD patients to be younger, but there are no notable trends with regard to gender. The BPD patients had a significantly earlier age of onset of their first major depressive episode. Both BPD and OPD patients were more likely to have chronic depressions (defined from the SCID as having been depressed for 50% or more of the last 5 years). The BPD patients were also rated as having a lower score on the GAF. The BPD patients had higher rates for some comorbid disorders. Interestingly, subtypes of major depression, such as melancholia, did not differ significantly across groups. The BPD patients had higher rates of suicide attempts and self-mutilation. While BPD patients did not significantly differ from the other depressed patients with regard to traditional DSM-IV diagnostic subtypes, on selfreport they rated themselves as more angry/hostile (see Table 3 ). The BPD patients also differed from the NPD patients with regard to phobic symptoms, interpersonal sensitivity, paranoid ideation, and psychoticism; however, they were not significantly different from the OPD depressed patients. The BPD patients had poorer social adjustment.
In Table 4 , we examine how the three groups of depressed patients vary on the TCI. The findings are consistent with those of Svrakic et al., 6 namely, the BPD patients have low scores on the character measures of self-directedness and cooperativeness, and high scores on the temperament measures of novelty seeking and harm avoidance. Table 5 shows the baseline MADRS, 6-week MADRS, and percent improvement on the MADRS. Of the 183 patients, 152 completed an adequate 6-week trial of the initial antidepressant to which they had been randomized. Using percent improvement on the MADRS as the key outcome variable, we ran a multiple regression analysis across the whole sample. Using drug (fluoxetine or nortriptyline), OPD (yes/no), and BPD (yes/no), percent improvement was predicted by BPD (P ϭ .026) and drug ϫ BPD (P ϭ .005). Table 5 shows that within those with BPD nortriptyline is inferior to fluoxetine (P ϭ .007). If a dichotomized outcome variable is used (Ն60% improvement on MADRS), then those with BPD have a lower response rate (using intention to treat) on nortriptyline (27%) compared with fluoxetine (67%) ( 2 ϭ 4.82, P ϭ .028) (Fig 1) .
Differential Treatment Response to Fluoxetine and Nortriptyline
Six-Month Outcome
Although all depressed patients were initially randomized to fluoxetine or nortriptyline, if after 6 weeks (or later) there was an inadequate remission of depressive symptoms, then clinicians changed antidepressant, usually swapping from nortriptyline to fluoxetine or vice versa. Thus, by 6 months, most patients who had not done well on their initial antidepressant had been trialed on both of the study antidepressants and often others as well. At 6 months, the group that was consistently doing worst was the group with OPD. The BPD patients were as well as the NPD patients. Table 6 shows scores on the TCI, which was repeated at 6 months. While there are still differences across the three personality disorder groups at 6 months, the most interesting findings reflect change from baseline, which can be seen by comparing data from Table 6 with those in Table 4 . Across the three groups, harm avoidance declines and self-directedness increases, presumably largely reflecting the impact of state depression. However, the most marked changes are seen in the BPD group.
Low self-directedness is the core character measure of individuals with personality disorders, and at baseline the BPD patients scored lower than the OPD patients who, in turn, scored lower than the NPD patients. However, by 6 months, the selfdirectedness of BPD patients had increased by more than 1 SD and, at 6 months, the OPD patients had the lowest self-directedness scores (Fig 2) . 
DISCUSSION
Comparison of BPD Patients With Other Depressed Patients
In this study, we recruited a large heterogenous sample of depressed patients, minimized exclusion criteria (especially those related to personality psychopathology and suicidal behavior), and randomized them to treatment with either fluoxetine or nortriptyline. Using DSM-III-R criteria for BPD, we created three groups of depressed patients. The group of depressed patients identified as having BPD clearly differed from the other depressed patients in a variety of ways, most of which were to be expected based on previous studies including an earlier study by ourselves. 19 Thus, the BPD patients were different from the NPD patients on self-report measures of anger/hostility, interpersonal sensitivity, paranoid ideation, and psychoticism, but anger/hostility was the key dimension upon which they differed from both other groups of depressed patients.
The BPD patients also had early onset, chronic depressive disorders, and poorer social functioning (especially in the interpersonal and friction domains), and had higher rates of comorbid social phobia and substance abuse/dependence. Perhaps the increased rates of comorbid social phobia is a surprise to some, but is consistent with the high harm avoidance scores in both the BPD and OPD groups. Not surprisingly, the BPD group had much higher rates of suicide attempts and self-mutilation.
The scores of the BPD patients on the TCI is remarkably consistent with the findings of Svrakic et al., 6 and is consistent with our own earlier work on the temperament of BPD patients. 20 In essence, the findings are that BPD patients score very low on the character measures of self-directedness and cooperativeness, and score high on the temperament measures of novelty seeking and harm avoidance.
Differential Antidepressant Response
One of the most important findings from this study is that when depressed patients with BPD are prescribed fluoxetine, the short-term antidepressant response is comparable to that achieved by depressed patients with no personality disorder. However, if depressed BPD patients receive nortriptyline, their short-term response to treatment is significantly worse compared with BPD patients prescribed fluoxetine, and significantly worse than depressed patients with NPD who receive either antidepressant drug. We are unaware of any other treatment trial in depressed BPD patients that has comparable results, but we think the results are consistent with emerging views on the pharmacotherapy of BPD.
Traditional clinical lore has been that depressed BPD patients respond poorly to most tricyclic antidepressant drugs; however, Fava et al. 21 have reported that depressed BPD patients respond favorably to fluoxetine. Earlier, Parsons et al. 22 reported that BPD patients with atypical depression responded especially well to phenelzine. Furthermore, Coccaro and Kavoussi 23 have reported that fluoxetine has an antiaggressive effect in impulsive aggressive individuals with personality disorder. Together, these reports are supportive of our findings regarding the favorable response to fluoxetine, despite a poor response to nortriptyline.
Six-Month Outcome
An important finding from this study is that, at 6 months, the BPD patients have a good outcome. With regard to depressive symptoms and social functioning, the BPD patients are doing as well as the NPD patients. Furthermore, the BPD patients have experienced a marked improvement in their character measures of cooperativeness and, especially, self-directedness.
In those with NPD the character measures of self-directness and cooperativeness changed slightly, probably largely reflecting some impact of depression on these character measures, as well as the temperament trait of harm avoidance. In those with BPD, the changes in self-directedness and cooperativeness were considerable and probably reflect some contribution from improvement in depression, but probably also reflects on important changes in personality psychopathology over 6 months.
In considering the favorable 6-month outcome, it is of relevance to reflect upon the treatment these patients received. While the study was primarily a pharmacological one to examine predictors of antidepressant response, considerable effort was made to optimize the pharmacotherapy. All depressed patients were essentially treated by a single psychiatrist or senior psychiatric resident over time. Patients were advised that we were offering this free treatment for a minimum of 2 years and, sometimes, longer. Patients were advised that we were interested in why some patients did well with antidepressant drugs and why others did poorly. We emphasized our interests in depressed patients who did poorly (and well) and our interests in personality traits of our patients. Patients also knew that, regardless of their wish to continue seeing us for treatment, we were keen to follow their outcome prospectively over 5 years. Finally, patients knew we were readily available and that there was some flexibility with regard to the scheduling of appointments. These ingredients contributed to a very supportive, long-term clinical relationship with high tolerance for a range of outcomes. Psychoeducation of patients about depression was also strongly encouraged, while specific psychotherapeutic approaches were neither encouraged nor discouraged. Thus, the consistent care and assertive follow-up may have contributed to the favorable outcome for the BPD patients at 6 months. However, the same improvements were not made by the depressed patients with OPD.
Limitations and Strengths
No one study can answer all questions about the important issue of BPD and major depression. The sample overall, however, was younger than many samples of depressed patients reported in the literature. Furthermore, although the study was undertaken within a University Clinical Research Unit, most patients had never previously received antidepressants in their lives and, for most, this was a first contact with specialist Mental Health Services.
While patients were randomized to their initial antidepressant, treatment was done openly (i.e., not double-blind), which reflects real life clinical practice. However, in considering our results over 6 weeks with fluoxetine and nortriptyline, the difference between these drugs in the BPD patients was not anticipated, and the improvement is obvious in self-report measures as well as clinician-rated measures.
A final limitation is that, in this study, we had the ability to offer depressed patients free, long-term treatment with a single psychiatrist, plus additional support from a psychiatric research nurse. Many public mental health services may be unable to provide such care and, in such instances, the favorable long-term outcomes may not be generalizable.
Conclusions
The major finding is that, if BPD patients with major depression are prescribed fluoxetine, their short-term response is as good as any other patient's with major depression. Furthermore, the 6-month outcome for the BPD depressed patients is also favorable when treated with appropriate psychopharmacological agents and in the context of consistent clinical care. Finally, not only do the depressed BPD patients do well over 6 months with regard to their depression, but the core character measure of self-directedness changes by over one standard deviation. Self-directedness, from Cloninger's psychobiological model of personality, both captured the severe character pathology of the BPD patients at baseline and changed over 6 months in response to treatment, suggesting that this is a useful measure for studying change in personality psychopathology.
